Cargando…
Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics
Substance abuse is a fundamentally dynamic disease, characterized by repeated oscillation between craving, drug self-administration, reward, and satiety. To model nicotine addiction as a control system, a magnetic resonance imaging (MRI)-compatible nicotine delivery system is needed to elicit cyclic...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708378/ https://www.ncbi.nlm.nih.gov/pubmed/34959350 http://dx.doi.org/10.3390/pharmaceutics13122069 |
_version_ | 1784622669901070336 |
---|---|
author | Kumar, Rajat Mujica-Parodi, Lilianne R. Wenke, Michael Amgalan, Anar Lithen, Andrew Govindarajan, Sindhuja T. Makaryus, Rany Benveniste, Helene Strey, Helmut H. |
author_facet | Kumar, Rajat Mujica-Parodi, Lilianne R. Wenke, Michael Amgalan, Anar Lithen, Andrew Govindarajan, Sindhuja T. Makaryus, Rany Benveniste, Helene Strey, Helmut H. |
author_sort | Kumar, Rajat |
collection | PubMed |
description | Substance abuse is a fundamentally dynamic disease, characterized by repeated oscillation between craving, drug self-administration, reward, and satiety. To model nicotine addiction as a control system, a magnetic resonance imaging (MRI)-compatible nicotine delivery system is needed to elicit cyclical cravings. Using a concentric nebulizer, inserted into one nostril, we delivered each dose equivalent to a single cigarette puff by a syringe pump. A control mechanism permits dual modes: one delivers puffs on a fixed interval programmed by researchers; with the other, subjects press a button to self-administer each nicotine dose. We tested the viability of this delivery method for studying the brain’s response to nicotine addiction in three steps. First, we established the pharmacokinetics of nicotine delivery, using a dosing scheme designed to gradually achieve saturation. Second, we lengthened the time between microdoses to elicit craving cycles, using both fixed-interval and subject-driven behavior. Finally, we demonstrate a potential application of our device by showing that a fixed-interval protocol can reliably identify neuromodulatory targets for pharmacotherapy or brain stimulation. Our MRI-compatible nasal delivery method enables the measurement of neural circuit responses to drug doses on a single-subject level, allowing the development of data-driven predictive models to quantify individual dysregulations of the reward control circuit causing addiction. |
format | Online Article Text |
id | pubmed-8708378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87083782021-12-25 Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics Kumar, Rajat Mujica-Parodi, Lilianne R. Wenke, Michael Amgalan, Anar Lithen, Andrew Govindarajan, Sindhuja T. Makaryus, Rany Benveniste, Helene Strey, Helmut H. Pharmaceutics Article Substance abuse is a fundamentally dynamic disease, characterized by repeated oscillation between craving, drug self-administration, reward, and satiety. To model nicotine addiction as a control system, a magnetic resonance imaging (MRI)-compatible nicotine delivery system is needed to elicit cyclical cravings. Using a concentric nebulizer, inserted into one nostril, we delivered each dose equivalent to a single cigarette puff by a syringe pump. A control mechanism permits dual modes: one delivers puffs on a fixed interval programmed by researchers; with the other, subjects press a button to self-administer each nicotine dose. We tested the viability of this delivery method for studying the brain’s response to nicotine addiction in three steps. First, we established the pharmacokinetics of nicotine delivery, using a dosing scheme designed to gradually achieve saturation. Second, we lengthened the time between microdoses to elicit craving cycles, using both fixed-interval and subject-driven behavior. Finally, we demonstrate a potential application of our device by showing that a fixed-interval protocol can reliably identify neuromodulatory targets for pharmacotherapy or brain stimulation. Our MRI-compatible nasal delivery method enables the measurement of neural circuit responses to drug doses on a single-subject level, allowing the development of data-driven predictive models to quantify individual dysregulations of the reward control circuit causing addiction. MDPI 2021-12-03 /pmc/articles/PMC8708378/ /pubmed/34959350 http://dx.doi.org/10.3390/pharmaceutics13122069 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kumar, Rajat Mujica-Parodi, Lilianne R. Wenke, Michael Amgalan, Anar Lithen, Andrew Govindarajan, Sindhuja T. Makaryus, Rany Benveniste, Helene Strey, Helmut H. Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics |
title | Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics |
title_full | Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics |
title_fullStr | Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics |
title_full_unstemmed | Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics |
title_short | Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics |
title_sort | development of an mri-compatible nasal drug delivery method for probing nicotine addiction dynamics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708378/ https://www.ncbi.nlm.nih.gov/pubmed/34959350 http://dx.doi.org/10.3390/pharmaceutics13122069 |
work_keys_str_mv | AT kumarrajat developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics AT mujicaparodililianner developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics AT wenkemichael developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics AT amgalananar developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics AT lithenandrew developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics AT govindarajansindhujat developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics AT makaryusrany developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics AT benvenistehelene developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics AT streyhelmuth developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics |